Eruptive Keratoacanthomas Associated With Pembrolizumab Therapy

IMPORTANCE: To our knowledge, there have been no previous reports of eruptive keratoacanthomas (KAs) in patients receiving pembrolizumab. OBJECTIVE: To report the cases of 3 consecutive patients with pembrolizumab-induced eruptive KAs and their management. DESIGN, SETTING, AND PARTICIPANTS: Case rep...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:JAMA Dermatol
Glavni autori: Freites-Martinez, Azael, Kwong, Bernice Y., Rieger, Kerri E., Coit, Daniel G., Colevas, A. Dimitrios, Lacouture, Mario E.
Format: Artigo
Jezik:Inglês
Izdano: American Medical Association 2017
Teme:
Brief Report
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5523926/
https://ncbi.nlm.nih.gov/pubmed/28467522
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamadermatol.2017.0989
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items